Jane Street Group Adds $22M in ADMA Biologics, Inc. ($ADMA)
Key Points
- Jane Street Group changed its ADMA Biologics, Inc. ($ADMA) stake by 564.3% last quarter, boosting to 3,051,943 shares worth $25.39 million.
- Wall Street's consensus rating on $ADMA is Buy and an average price target of $17.60.
- $ADMA last traded around $8.32.
Jane Street Group increased its position in ADMA Biologics, Inc. ($ADMA) by 564.3% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,051,943 shares of ADMA Biologics, Inc. after buying 2,592,519 shares during the quarter. Jane Street Group's holdings in ADMA Biologics, Inc. were worth $25.39 million as of its most recent filing.
ADMA Biologics, Inc. ($ADMA) Stock
ADMA Biologics, Inc. Earnings
Analysts Set New Price Targets
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.